Consensus Dr. Reddy's Laboratories Limited

Stocks

DRREDDY

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. 13:02:28 04/09/2026 +03			5-day change	1st Jan Change
1,154.00 ^INR	-0.09%		-2.02%	-9.21%

09-03	Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading	MT
09-03	Aspen sees Mounjaro Africa sales above $124 million in 2027	RE

Evolution of the Average Target: Dr. Reddy's Laboratories Limited

Evolution of the Target Price: Dr. Reddy's Laboratories Limited

Changes in Analyst Recommendations: Dr. Reddy's Laboratories Limited

e76813c8.B3lGINQl4tjy0PymIE6Eg76id6YYT8TYiuCfrgCcOng.TwkxVrpLoIi95J78Vhvl-uyVPZJuPLzp69Hlg2ntchF1IChU5mun7rG7sQ~22a479c4f526c03d309ab97f835eb02d

Analysts' recommendations: Dr. Reddy's Laboratories Limited

07-10	Elara Securities India Downgrades Dr. Reddy's Laboratories to Reduce From Accumulate; Price Target is INR1,283	MT
06-22	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,740 From INR1,600, Keeps at Buy	MT
01-23	YES Research Upgrades Dr. Reddy's Laboratories to Add from Reduce, Price Target is INR1,340	MT
01-23	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,600 From INR1,580, Keeps at Buy	MT
01-22	ICICI Securities Upgrades Dr. Reddy's Laboratories to Add from Hold, Price Target is INR1,300	MT
01-22	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,040 from INR1,100, Keeps at Underperform	MT
30/10/25	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,580 From INR1,650, Keeps at Buy	MT
27/10/25	Choice Equity Upgrades Dr. Reddy's Laboratories to Add from Reduce; Price Target is INR1,380	MT
27/10/25	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,650 From INR1,660, Keeps at Buy	MT
27/10/25	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,100, Keeps at Underperform	MT
13/10/25	BNP Paribas Exane Initiates Dr. Reddy's Laboratories at Neutral With $13.18 Price Target	MT
25/07/25	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,660 From INR1,575, Keeps at Buy	MT
24/07/25	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,100 From INR1,010, Keeps at Underperform	MT
12/05/25	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,010 from INR1,170, Keeps at Underperform	MT
27/01/25	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,575 From INR1,500, Keeps at Buy	MT
24/01/25	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,170 From INR1,210, Keeps at Underperform	MT
20/12/24	Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees	MT
06/11/24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform	MT
29/07/24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR5,600 From INR5,010, Keeps at Underperform	MT
08/05/24	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform	MT
29/01/24	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating	MT
30/10/23	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy	MT
27/07/23	Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy	MT
01/06/23	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating	MT
30/01/23	Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DR. REDDY'S LABORATORIES LIMITED					+9.69%
	ELI LILLY AND COMPANY					+14.46%
	JOHNSON & JOHNSON					+0.15%
	ABBVIE INC.					+7.85%
	ROCHE HOLDING AG					+3.73%
	NOVARTIS AG					-3.15%
	ASTRAZENECA PLC					+31.21%
	AMGEN INC.					-10.87%
	NOVO NORDISK A/S					+3.62%
	GILEAD SCIENCES, INC.					+4.25%
	Average					+6.09%
	Weighted average by Cap.					+6.98%